meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced UC (mUC) - 2nd Line (L2)
mUC - L2 - all population
2
mUC - L2 - PDL1 positive
3
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
pembrolizumab based treatment
pembrolizumab alone
versus all
vs chemotherapy
vs Standard of Care (SoC)
All patients
ECOG 0
ECOG 1
Hemoglobin concentration < 10g/dl
hemoglobin concentration > 10g/dl
metastasis (liver )
metastasis (lymph node )
smoker (Current)
smoker (Former)
smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
deaths (OS) (extension)
DOR
objective responses (ORR)
progression or deaths (PFS)
AE (any grade)
AE (grade 3-4)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
SAE (any grade)
STRAE (any grade)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
Anaemia TRAE (grade 3-4)
Asthenia TRAE (grade 3-4)
Constipation TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Febrile neutropenia TRAE (grade 3-4)
Neutropenia TRAE (grade 3-4)
Peripheral neuropathy TRAE (grade 3-4)
deaths (OS)
mUC - L2 - PDL1 positive
metastatic/advanced UC (mUC) - 2nd Line (L2)
mUC - L2 - PDL1 positive
versus Standard of Care (SoC)
atezolizumab alone vs. Standard of Care (SoC)
2
certainty unassessable
-12%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open